CN104080772B - 抗凝血逆转剂 - Google Patents

抗凝血逆转剂 Download PDF

Info

Publication number
CN104080772B
CN104080772B CN201280060950.2A CN201280060950A CN104080772B CN 104080772 B CN104080772 B CN 104080772B CN 201280060950 A CN201280060950 A CN 201280060950A CN 104080772 B CN104080772 B CN 104080772B
Authority
CN
China
Prior art keywords
dap
compound
anticoagulant
pharmaceutically acceptable
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280060950.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN104080772A (zh
Inventor
S·S·斯泰纳尔
B·E·劳利希特
S·H·贝克鲁
E·马希奥维茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kewei Medical Holding Co Ltd
Sila Patra Holding Ltd
Xirapathe Holding Co Ltd
Original Assignee
Perosphere Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47430065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104080772(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Perosphere Inc filed Critical Perosphere Inc
Publication of CN104080772A publication Critical patent/CN104080772A/zh
Application granted granted Critical
Publication of CN104080772B publication Critical patent/CN104080772B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201280060950.2A 2011-11-29 2012-11-29 抗凝血逆转剂 Active CN104080772B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161564559P 2011-11-29 2011-11-29
US61/564,559 2011-11-29
US201261614292P 2012-03-22 2012-03-22
US61/614,292 2012-03-22
US201261641698P 2012-05-02 2012-05-02
US61/641,698 2012-05-02
US201261666291P 2012-06-29 2012-06-29
US61/666,291 2012-06-29
PCT/US2012/066938 WO2013082210A1 (en) 2011-11-29 2012-11-29 Anticoagulant reversal agents

Publications (2)

Publication Number Publication Date
CN104080772A CN104080772A (zh) 2014-10-01
CN104080772B true CN104080772B (zh) 2016-10-05

Family

ID=47430065

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280060950.2A Active CN104080772B (zh) 2011-11-29 2012-11-29 抗凝血逆转剂

Country Status (34)

Country Link
US (5) US9522892B2 (cg-RX-API-DMAC7.html)
EP (1) EP2785700B1 (cg-RX-API-DMAC7.html)
JP (1) JP6134731B2 (cg-RX-API-DMAC7.html)
KR (1) KR101892330B1 (cg-RX-API-DMAC7.html)
CN (1) CN104080772B (cg-RX-API-DMAC7.html)
AP (1) AP2014007662A0 (cg-RX-API-DMAC7.html)
AR (1) AR089020A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012345975B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014012892B1 (cg-RX-API-DMAC7.html)
CA (1) CA2856540C (cg-RX-API-DMAC7.html)
CL (1) CL2014001399A1 (cg-RX-API-DMAC7.html)
CO (1) CO6990738A2 (cg-RX-API-DMAC7.html)
CR (1) CR20140310A (cg-RX-API-DMAC7.html)
CY (1) CY1117414T1 (cg-RX-API-DMAC7.html)
DK (1) DK2785700T3 (cg-RX-API-DMAC7.html)
EA (1) EA027603B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP14006696A (cg-RX-API-DMAC7.html)
ES (1) ES2569674T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20160513T1 (cg-RX-API-DMAC7.html)
HU (1) HUE027452T2 (cg-RX-API-DMAC7.html)
IL (1) IL232788B (cg-RX-API-DMAC7.html)
ME (1) ME02424B (cg-RX-API-DMAC7.html)
MX (1) MX349514B (cg-RX-API-DMAC7.html)
PE (1) PE20141295A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014501176B1 (cg-RX-API-DMAC7.html)
PL (1) PL2785700T3 (cg-RX-API-DMAC7.html)
PT (1) PT2785700E (cg-RX-API-DMAC7.html)
RS (1) RS54738B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201402713WA (cg-RX-API-DMAC7.html)
SI (1) SI2785700T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201600161B (cg-RX-API-DMAC7.html)
UA (1) UA116336C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013082210A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201404793B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015069844A1 (en) * 2013-11-08 2015-05-14 Perosphere Inc. Labeled compounds and methods of imaging, diagnosing cartilage disorders and diseases, and monitoring cartilage health using labeled and unlabeled compounds
TWI828027B (zh) 2016-03-28 2024-01-01 美商英塞特公司 作為tam抑制劑之吡咯并三嗪化合物
US10633387B2 (en) 2017-09-27 2020-04-28 Incyte Corporation Salts of TAM inhibitors
PE20200719A1 (es) * 2017-11-13 2020-07-21 Maximum Fidelity Surgical Simulations Llc Reconstitucion de la circulacion posmortem, metodos y procedimientos especializados
ES3031110T3 (en) 2018-06-29 2025-07-04 Incyte Corp Formulations of an axl/mer inhibitor
US11716989B2 (en) 2019-04-16 2023-08-08 Maximum Fidelity Surgical Simulations, LLC Cadaver preservation systems and methods
US11915610B2 (en) 2019-05-15 2024-02-27 Maximum Fidelity Surgical Simulations, LLC Cadaverous heart model
CN112010930B (zh) * 2019-05-28 2022-08-02 首都医科大学 Rgd修饰的五环哌嗪二酮及其制备和应用
PH12022552347A1 (en) 2020-03-06 2024-01-29 Incyte Corp Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
EP4692086A1 (en) 2023-03-24 2026-02-11 Shaanxi Micot Pharmaceutical Technology Co., Ltd. Anticoagulation reversal agent, and preparation method therefor and use thereof
CN117624137A (zh) * 2023-12-04 2024-03-01 中国药科大学 三嗪骨架小分子肝素逆转剂及其制备方法与用途
US20250389737A1 (en) * 2024-06-20 2025-12-25 Instrumentation Laboratory Company FACTOR Xa REAGENT
EP4667582A1 (en) * 2024-06-20 2025-12-24 Instrumentation Laboratory Company Factor xa reagent
CN121622691A (zh) * 2024-08-30 2026-03-10 陕西麦科奥特医药科技股份有限公司 使用抗凝逆转剂治疗抗凝剂导致的出血的方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010022A1 (en) * 1994-09-26 1996-04-04 Zeneca Limited Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents
WO1997012904A1 (en) * 1995-10-02 1997-04-10 Hoechst Marion Roussel, Inc. Polyfluoroalkyl tryptophan tripeptide thrombin inhibitors
CN1314895A (zh) * 1998-07-17 2001-09-26 L·拉峰试验公司 取代的哌嗪酮及其治疗应用
US20020022614A1 (en) * 2000-06-29 2002-02-21 Pinto Donald J.P. Thrombin or factor Xa inhibitors
US6403583B1 (en) * 1998-12-23 2002-06-11 Patrick Y. S. Lam Thrombin or factor Xa inhibitors
CN1905883A (zh) * 2004-01-08 2007-01-31 阿斯利康(瑞典)有限公司 6－{4－[4－(1h－吲哚－2－磺酰基)－哌嗪－1－羰基－苯基]}哒嗪－3－酮的新衍生物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3678157A (en) * 1968-10-23 1972-07-18 Oreal Hair treatment compositions containing polycondensable compounds
US6080852A (en) 1996-06-27 2000-06-27 The Perkin-Elmer Corporation 4,7-dichlororhodamine dyes
CA2268381A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Selective factor xa inhibitors
CA2285454A1 (en) * 1997-04-07 1998-10-15 Axys Pharmaceuticals Corporation Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, activity
JP2002544263A (ja) 1999-05-19 2002-12-24 ファルマシア・コーポレイション 抗凝血剤としての置換多環式アリールおよびヘテロアリールウラシル
CA2412345A1 (en) 1999-06-16 2000-12-21 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
EP1274676A2 (en) 2000-04-17 2003-01-15 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
BR0213092A (pt) 2001-10-03 2004-10-19 Pharmacia Corp Compostos heterocìclicos de 6 elementos úteis para a inibição seletiva da cascata de coagulação
WO2003082809A1 (en) * 2002-03-27 2003-10-09 Glaxo Group Limited Diaminoacid-aminoacid-polyamine based gemini surfactant compounds
JPWO2003099324A1 (ja) * 2002-05-23 2005-09-22 中外製薬株式会社 組織因子阻害剤中和剤及び活性型血液凝固第ｖｉｉ因子製剤中和剤
GB0214122D0 (en) 2002-06-19 2002-07-31 Eastman Kodak Co High contrast photographic element containing a polyhydrazide nucleating agent
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
JPWO2008105441A1 (ja) * 2007-02-27 2010-06-03 味の素株式会社 リン吸収抑制活性を有するポリアミノ酸化合物及びリン吸収抑制剤
KR102069498B1 (ko) * 2007-09-28 2020-01-23 포톨라 파마슈티컬스, 인코포레이티드 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법
GB2476643B (en) 2009-12-23 2012-11-14 Haomamedica Ltd 1,4-Dihydro-1,4-dioxonaphtalene derivatives as anticoagulants
TWI513466B (zh) 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑
EA201301090A1 (ru) 2011-03-30 2014-05-30 Бёрингер Ингельхайм Интернациональ Гмбх Антидоты антикоагулянтов

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010022A1 (en) * 1994-09-26 1996-04-04 Zeneca Limited Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents
WO1997012904A1 (en) * 1995-10-02 1997-04-10 Hoechst Marion Roussel, Inc. Polyfluoroalkyl tryptophan tripeptide thrombin inhibitors
CN1198748A (zh) * 1995-10-02 1998-11-11 赫彻斯特马里恩鲁斯公司 多氟烷基色氨酸三肽凝血酶抑制剂
CN1314895A (zh) * 1998-07-17 2001-09-26 L·拉峰试验公司 取代的哌嗪酮及其治疗应用
US6403583B1 (en) * 1998-12-23 2002-06-11 Patrick Y. S. Lam Thrombin or factor Xa inhibitors
US20020022614A1 (en) * 2000-06-29 2002-02-21 Pinto Donald J.P. Thrombin or factor Xa inhibitors
CN1905883A (zh) * 2004-01-08 2007-01-31 阿斯利康(瑞典)有限公司 6－{4－[4－(1h－吲哚－2－磺酰基)－哌嗪－1－羰基－苯基]}哒嗪－3－酮的新衍生物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents;Mark A. Crowther,等;《BLOOD》;20080515;第111卷(第10期);第4874页表2 *
Guanidines with Antihypertensive Activity.II;Robert P. Mull,等;《Journal of medicinal and pharmaceutical chemistry》;19621231;第5卷;第948页表III *
Heterocyclic Quinones VIII. Synthesis and spectra of new carbazoloquinone derivatives of naturally occurring amino acids;Ahmed Sabet Hammam;《Journal of Applied Chemistry and Biotechnology》;19761231;第26卷(第1期);第670页 *
Potent Dibasic GPIIb/IIIa Antagonists with Reduced Prolongation of Bleeding Time: Synthesis and Pharmacological Evaluation of 2-Oxopiperazine Derivatives;Shuji Kitamura,等;《Journal of Medicinal Chemistry》;20010621;第44卷(第15期);第2443页表3 *
Preparation of some substituted guanidines;Fritz Bischoff;《The Journal of Biological Chemistry》;19281231;第80卷;第347页 *

Also Published As

Publication number Publication date
UA116336C2 (uk) 2018-03-12
SI2785700T1 (sl) 2016-09-30
CA2856540C (en) 2018-04-03
US20180207152A1 (en) 2018-07-26
US20210169874A1 (en) 2021-06-10
BR112014012892A8 (pt) 2021-06-08
IL232788A0 (en) 2014-08-03
PE20141295A1 (es) 2014-10-01
AR089020A1 (es) 2014-07-23
ME02424B (me) 2016-09-20
CY1117414T1 (el) 2017-04-26
HK1202858A1 (en) 2015-10-09
US20240366592A1 (en) 2024-11-07
HRP20160513T1 (hr) 2016-07-15
EP2785700B1 (en) 2016-03-09
ZA201404793B (en) 2015-04-29
US9522892B2 (en) 2016-12-20
PL2785700T3 (pl) 2016-09-30
SMT201600161B (it) 2016-07-01
CO6990738A2 (es) 2014-07-10
BR112014012892B1 (pt) 2022-12-20
MX349514B (es) 2017-08-02
CR20140310A (es) 2014-08-20
NZ625337A (en) 2016-11-25
DK2785700T3 (en) 2016-06-13
EA201490823A1 (ru) 2015-01-30
EA027603B1 (ru) 2017-08-31
US20170056396A1 (en) 2017-03-02
CA2856540A1 (en) 2013-06-06
JP2014534270A (ja) 2014-12-18
AU2012345975B2 (en) 2016-12-15
IL232788B (en) 2018-05-31
ECSP14006696A (es) 2015-06-30
ES2569674T3 (es) 2016-05-12
KR20140107259A (ko) 2014-09-04
KR101892330B1 (ko) 2018-08-27
RS54738B1 (sr) 2016-10-31
BR112014012892A2 (pt) 2017-06-13
US20130137702A1 (en) 2013-05-30
JP6134731B2 (ja) 2017-05-24
AP2014007662A0 (en) 2014-05-31
SG11201402713WA (en) 2014-06-27
HUE027452T2 (en) 2016-09-28
AU2012345975A1 (en) 2014-05-29
CL2014001399A1 (es) 2014-11-03
US9877961B2 (en) 2018-01-30
PT2785700E (pt) 2016-06-02
WO2013082210A1 (en) 2013-06-06
PH12014501176A1 (en) 2014-09-01
CN104080772A (zh) 2014-10-01
EP2785700A1 (en) 2014-10-08
PH12014501176B1 (en) 2014-09-01
MX2014006349A (es) 2014-09-04

Similar Documents

Publication Publication Date Title
US20240366592A1 (en) Anticoagulant reversal agents
ES2384116T3 (es) Sales y polimorfos farmacéuticos de N-(5-cloro-2-piridinil)-2-[[4-[(dimetilamino)iminometil]benzoil]amino]-5-metoxi-benzamida, un inhibidor del factor XA
CZ287725B6 (en) Medicament for thrombin inhibition and for suppressing treated disease or a state where thrombin inhibition is needful
CN102325768B (zh) 治疗疼痛和其他疾病的化合物和方法
WO2016034137A1 (zh) 吡唑并[3，4-c]吡啶类衍生物
EP4692086A1 (en) Anticoagulation reversal agent, and preparation method therefor and use thereof
HK1202858B (en) Anticoagulant reversal agents
CN103880797B (zh) 苯并呋喃类化合物及其医药用途
OA16905A (en) Anticoagulant reversal agents.
CN105367622B (zh) 一种阿加曲班化合物
NZ625337B2 (en) Anticoagulant reversal agents
WO2003055525A1 (fr) Preparations contenant un acide
WO2020094008A1 (zh) 2-氧代-1，2-二氢喹啉类衍生物、其制备方法及其在医药上的应用
KR20210046115A (ko) 니아신 유도체 및 이를 함유하는 약학 조성물
CN101511816B (zh) 具有改善的生物利用度的氨基异喹啉凝血酶抑制剂
HK40123243A (en) Compositions and methods for treating hepatic porphyrias with glycine transport inhibitors
JP2004511489A (ja) ポリヒドロキシアルキル基およびポリヒドロキシシクロアルキル基を有するセリンプロでアーゼの低分子インヒビター
JPWO1999011617A1 (ja) 新規なナフトアミド誘導体又はその塩

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1202858

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1202858

Country of ref document: HK

CP01 Change in the name or title of a patent holder

Address after: American Connecticut

Patentee after: Peiros Phil pharmaceutical Co.

Address before: American Connecticut

Patentee before: PEROSPHERE INC.

CP01 Change in the name or title of a patent holder
TR01 Transfer of patent right

Effective date of registration: 20230626

Address after: Swiss Express

Patentee after: Kravis Pharmaceuticals Co.,Ltd.

Address before: Connecticut USA

Patentee before: Peiros Phil pharmaceutical Co.

TR01 Transfer of patent right
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: Switzerland

Patentee after: Sila Patra Holding Limited

Country or region after: Switzerland

Address before: Switzerland

Patentee before: Kewei Medical Holding Co., Ltd.

Country or region before: Switzerland

Address after: Luxembourg

Patentee after: Xirapathe Holding Co., Ltd.

Country or region after: Luxembourg

Address before: Switzerland

Patentee before: Sila Patra Holding Limited

Country or region before: Switzerland

TR01 Transfer of patent right

Effective date of registration: 20251216

Address after: Switzerland

Patentee after: Kewei Medical Holding Co., Ltd.

Country or region after: Switzerland

Address before: Chug, Switzerland

Patentee before: Kravis Pharmaceuticals Co.,Ltd.

Country or region before: Switzerland

TR01 Transfer of patent right